Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07042295 · ClinicalTrials.gov registry record · Phase 2
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
A Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Locally Recurrent Skin Squamous Cell Carcinoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 9
- Study locations
NCT07042295: Recruiting Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Locally Recurrent Skin Squamous Cell Carcinoma, sponsored by National Cancer Institute (NCI).
NCT07042295 is a Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Locally Recurrent Skin Squamous Cell Carcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 86 participants, above the 49-participant average among 5 other Metastatic Skin Squamous Cell Carcinoma trials with a reported enrollment target (76% higher). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07042295, a Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Locally Recurrent Skin Squamous Cell Carcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase II trial compares the effect of amivantamab and hyaluronidase to cetuximab for the treatment of skin (cutaneous) squamous cell carcinoma that has come back after a period of improvement and has not spread to other parts of the body (locally recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Amivantamab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Hyaluronidase is an endoglycosidase. It helps to keep amivantamab in the body longer, so that the medications will have a greater effect. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Giving amivantamab and hyaluronidase may be as effective as cetuximab for the treatment of locally recurrent or metastatic cutaneous squamous cell carcinoma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- BIOLOGICAL Cetuximab
- DRUG Amivantamab and Recombinant Human Hyaluronidase
Study Locations (9)
Illinois
- Carle at The Riverfront - Danville
- Carle Physician Group-Effingham - Effingham
- Carle Physician Group-Mattoon/Charleston - Mattoon
- Carle BroMenn Medical Center - Normal
- Carle Cancer Institute Normal - Normal
- Carle Cancer Center - Urbana
California
- UC San Diego Moores Cancer Center - La Jolla
Connecticut
- Yale University - New Haven
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2026-10-25 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
What NCT07042295 shows while recruiting
NCT07042295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 49-participant average among 5 other Metastatic Skin Squamous Cell Carcinoma trials with a reported enrollment target (76% higher).
The record links to 2 conditions, with Metastatic Skin Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07042295 lists 9 locations in 4 states (Illinois, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT07042295 about?
NCT07042295 is a clinical study titled "Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System". This phase II trial compares the effect of amivantamab and hyaluronidase to cetuximab for the treatment of skin (cutaneous) squamous cell carcinoma that has come back after a period of improvement and has not spread to other parts of the body (locally recurrent) or that has spread from where it firs...
What is the current status of trial NCT07042295?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2026-10-25. Estimated completion is 2029-02-28.
What conditions does trial NCT07042295 study?
This clinical trial studies the following conditions: Metastatic Skin Squamous Cell Carcinoma, Locally Recurrent Skin Squamous Cell Carcinoma.
What interventions are being tested in trial NCT07042295?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Cetuximab (BIOLOGICAL), Amivantamab and Recombinant Human Hyaluronidase (DRUG).
Who is sponsoring clinical trial NCT07042295?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07042295 being conducted?
This trial has 9 study locations across California, Connecticut, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Skin Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
ACTIVE NOT RECRUITING · Phase 2
-
Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
COMPLETED · Phase 2
-
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
RECRUITING · Phase 1
-
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
RECRUITING · Phase 1
-
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI